✨
AI Summary & Key Takeaways
AI Insight⚡ TL;DR(Too Long; Didn't Read)
Once-daily treatment with PTH 1-34 maintained serum calcium within the normal range and reduced the dose of previous medical therapies.
📌 3 Key Takeaways
🎯
Objective & Hypothesis:Postsurgical chronic hypoparathyroidism is most commonly seen in adults.
📊
Key Findings & Data:Synthetic recombinant human parathyroid hormone (rhPTH) 1-34 can be used to stabilize serum calcium levels in patients with resistant hypocalcemia in rare conditions.
💡
Conclusion & Impact:Once-daily treatment with PTH 1-34 maintained serum calcium within the normal range and reduced the dose of previous medical therapies.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Hypoparathyroidism · Hypocalcemia · Teriparatide
Abstract
Postsurgical chronic hypoparathyroidism is most commonly seen in adults. Synthetic recombinant human parathyroid hormone (rhPTH) 1-34 can be used to stabilize serum calcium levels in patients with resistant hypocalcemia in rare conditions. Here we report a 52-year-old woman with postsurgical uncontrolled hypocalcemia despite the usual therapy. Once-daily treatment with PTH 1-34 maintained serum calcium within the normal range and reduced the dose of previous medical therapies.
🔖
Cite This Article
AYDEMİR, E., ERSOY, C., GÜL, Ö. Ö., CANDER, S., ÜNSAL, Y. A., ATEŞ, C., ERTÜRK, E. (2021). A Case of Resistant Hypocalcemia Treated with Teriparatide. Turkish Journal of Internal Medicine, Cilt: 3 - Sayı: Supplement 1, 92–93. https://ajindex.com/articles/809089